Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06020118 · ClinicalTrials.gov registry record · Phase 4
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 455
- Enrollment target
NCT06020118 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 455 participants.
The verdict
NCT06020118, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 455 participants
- Enrollment target
Study Summary
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
Interventions
- BIOLOGICAL Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
- BIOLOGICAL Sequential Vaccination (Influenza vaccine then mRNA COVID booster)
- BIOLOGICAL Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2023-09-25 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06020118
The ClinicalTrials.gov registry entry for NCT06020118 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster) is the first listed.
NCT06020118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06020118 about?
NCT06020118 is a clinical study titled "Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations". This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
What is the current status of trial NCT06020118?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 455 participants. The study started on 2023-09-25. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT06020118?
The interventions under investigation include: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster) (BIOLOGICAL), Sequential Vaccination (Influenza vaccine then mRNA COVID booster) (BIOLOGICAL), Sequential Vaccination (mRNA COVID booster then Influenza vaccine) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06020118?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.